An immunogenic personal neoantigen vaccine for patients with melanoma
By P. Ott, Zhuting Hu, D. Keskin, S. Shukla, Jing Sun, David j. Bozym, Wandi Zhang, Adrienne M. Luoma, A. Giobbie-Hurder, Lauren Peter and 30 more. Nature, 2017
2,625 citations recorded by the source corpus.
Subfields: Immunology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/4424fbeb9541a2ae663229e1d6b3fa9adda8d07a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- Nicholas McGranahan
- Charles Swanton
- Sandra Hervás-Stubbs
- I. Melero
- Aviv Regev
- K. Flaherty
- G. Getz
- Catherine J. Wu
In Molecular Biology
- Aviv Regev
- Nicholas McGranahan
- Eric S. Lander
- Charles Swanton
- Stacey Gabriel
- Tatiana T. Marquez-Lago
- Fuyi Li
- Shutao Mei
In Oncology
- Nicholas McGranahan
- Charles Swanton
- M. Hellmann
- J. Wolchok
- M. Callahan
- K. Flaherty
- I. Melero
- Catherine J. Wu
Citations in the corpus
- mRNA-based therapeutics: powerful and versatile tools to combat diseases (2022, background): “Recently, several clinical trials have been launched to further evaluate the antitumor efficacy of personal mRNA vaccines (NCT03313778, NCT02316457, and NCT03468244, relevant results have not yet been announced).(380,381) Collectively, based on the complexity of tumor pathogenesis, codelivery of mul”
- Advances in immunotherapy for hepatocellular carcinoma (2021, background): “I.M. receives funding from MINECO SAF2014-52361-R and SAF 2017- 83267-C2-1R; Worldwide Cancer Research Grant (15-1146); the Asociacion Española Contra el Cancer (AECC) Foundation under grant GCB15152947MELE; and the European Union’s Horizon 2020 Program (grant agreement no. 635122 PROCROP).”
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial (2018, methodology): “Next, we defined expression scores, for each cell, for the following genes and signatures, based on the average E of the gene(s) indicated in parenthesis: (1) CD4 (CD4); (2) CD8 (CD8A and CD8B); (3) regulatory T (Treg) cells (FOXP3 and IL2RA); (4) cytotoxic T cells (PRF1, GZMA, GZMK, NKG7 and CST7);”
- MHCflurry: open-source class I MHC binding affinity prediction (2017, background): “[4] Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, South Carolina, USA”
- Genomic features of response to combination immunotherapy in patients with advanced non-small cell lung cancer (2018, background): “, 2017) are critical, especially aspersonalized vaccine strategies targeting tumor-specific predicted neoantigens are now under way in the clinic (Ott et al., 2017; Sahin et al., 2017).”
- Neoantigens: promising targets for cancer therapy (2023, background): “Nevertheless, experimental and theoretical improvements are required to address the time and economic issues for advanced personalized neoantigen-based immunotherapies, including efficient recruitment of patients, optimizing sequencing technology and neoantigen prediction algorithms, and taking off-”